Government Regulation

November 15, 2019

Health Care Transparency

In Shock To $3.5 Trillion Healthcare Industry, Admin Will Force Hospitals To Disclose “Secret” Insurance Rates

In a move that will send shockwaves across the $3.5 trillion US healthcare industry, on Friday the Trump administration unveiled a plan that would – for the first time – force hospitals and insurers to disclose their secret negotiated rates, the WSJ reported.

In hopes of bringing some transparency and openness to a pathologically opaque industry, one which many have blamed for being behind the explosion in US underfunded liabilities to more than $100 trillion, administration officials said the final rule will compel hospitals in 2021 to publicize the rates they negotiate with individual insurers for all services, including drugs, supplies, facility fees and care by doctors who work for the facility. The White House would also propose extending the disclosure requirement to the $670 billion health-insurance industry. Insurance companies and group health plans that cover employees would have to disclose negotiated rates, as well as previously paid rates for out-of-network treatment, in computer-searchable file formats.

As the WSJ notes, the proposal covering insurers is the newest part of the price-disclosure initiative, and would include the private-employer market, where about 158 million people get their health insurance. Insurers and group health plans would have to put the negotiated rates into a file that third-party developers could incorporate into shopping tools. As with hospitals, insurers will have to create a web-based tool for beneficiaries that discloses the list price, the negotiated rate, cost sharing, and the amount left on a plan deductible, as well as allowable out-of-network rates.

The requirements, which are more far-reaching than industry leaders had expected, could upend commercial health-care markets, which are rife with purposefully complex systems of hidden charges and secret discounts which enable the fleecing of either end users or chronically  underfunded government healthcare programs. The price-disclosure initiative has become a cornerstone of the president’s 2020 re-election health strategy, despite threats of legal action from industry.

“Right now there is too much arbitrage in the system,” a senior administration official said in an interview Thursday with The Wall Street Journal. “There are a ton of vested interests who will oppose this. We expect to get sued. We’re really goring people’s oxes.”

Hospitals and insurers typically treat specific prices for medical services as closely held secrets, with contracts between the insurers and hospital systems generally bound by confidentiality agreements. Policy makers, employers and patients are often unable to see clearly which hospital systems and doctor practices are driving high costs.

Ironically just a few days ago we showed why “US Healthcare Costs Are Exploding“, and the primary culprit was soaring insurance and medical care service fees. If there is one thing that could potentially put a dent in this exponential surge, it is the elimination of all the various secret price deals and arrangements.

Why is transaprency good? Because as studies have shown, consumers are often required to pay more out of pocket when they don’t have the price information they need to comparison shop. Employer health-plan deductibles are outpacing wage growth and have risen to an average $1,655 for a single plan, according to a September survey by the Kaiser Family Foundation. Workers on average pay $6,015 toward the cost of their coverage.

Taken together, the WSJ notes, “the price-disclosure initiatives could reshape the $3.5 trillion health-care industry.”

The good news: the much needed transparency finally may bring some – literal – price discovery to what has traditionally been the most opaque, and lucrative, sector for the aging and chronically obese US population.

Meanwhile, as Americans lament soaring prices of, well, everything, after shelter and rent costs, the second biggest drain of US household income and savings is insurance premiums.

https://www.zerohedge.com/health/shock-35-trillion-healthcare-industry-trump-admin-will-force-hospitals-disclose-secret

November 15, 2019

Health Care Transparency

In Shock To $3.5 Trillion Healthcare Industry, Admin Will Force Hospitals To Disclose “Secret” Insurance Rates

In a move that will send shockwaves across the $3.5 trillion US healthcare industry, on Friday the Trump administration unveiled a plan that would – for the first time – force hospitals and insurers to disclose their secret negotiated rates, the WSJ reported.

In hopes of bringing some transparency and openness to a pathologically opaque industry, one which many have blamed for being behind the explosion in US underfunded liabilities to more than $100 trillion, administration officials said the final rule will compel hospitals in 2021 to publicize the rates they negotiate with individual insurers for all services, including drugs, supplies, facility fees and care by doctors who work for the facility. The White House would also propose extending the disclosure requirement to the $670 billion health-insurance industry. Insurance companies and group health plans that cover employees would have to disclose negotiated rates, as well as previously paid rates for out-of-network treatment, in computer-searchable file formats.

As the WSJ notes, the proposal covering insurers is the newest part of the price-disclosure initiative, and would include the private-employer market, where about 158 million people get their health insurance. Insurers and group health plans would have to put the negotiated rates into a file that third-party developers could incorporate into shopping tools. As with hospitals, insurers will have to create a web-based tool for beneficiaries that discloses the list price, the negotiated rate, cost sharing, and the amount left on a plan deductible, as well as allowable out-of-network rates.

The requirements, which are more far-reaching than industry leaders had expected, could upend commercial health-care markets, which are rife with purposefully complex systems of hidden charges and secret discounts which enable the fleecing of either end users or chronically  underfunded government healthcare programs. The price-disclosure initiative has become a cornerstone of the president’s 2020 re-election health strategy, despite threats of legal action from industry.

“Right now there is too much arbitrage in the system,” a senior administration official said in an interview Thursday with The Wall Street Journal. “There are a ton of vested interests who will oppose this. We expect to get sued. We’re really goring people’s oxes.”

Hospitals and insurers typically treat specific prices for medical services as closely held secrets, with contracts between the insurers and hospital systems generally bound by confidentiality agreements. Policy makers, employers and patients are often unable to see clearly which hospital systems and doctor practices are driving high costs.

Ironically just a few days ago we showed why “US Healthcare Costs Are Exploding“, and the primary culprit was soaring insurance and medical care service fees. If there is one thing that could potentially put a dent in this exponential surge, it is the elimination of all the various secret price deals and arrangements.

Why is transaprency good? Because as studies have shown, consumers are often required to pay more out of pocket when they don’t have the price information they need to comparison shop. Employer health-plan deductibles are outpacing wage growth and have risen to an average $1,655 for a single plan, according to a September survey by the Kaiser Family Foundation. Workers on average pay $6,015 toward the cost of their coverage.

Taken together, the WSJ notes, “the price-disclosure initiatives could reshape the $3.5 trillion health-care industry.”

The good news: the much needed transparency finally may bring some – literal – price discovery to what has traditionally been the most opaque, and lucrative, sector for the aging and chronically obese US population.

Meanwhile, as Americans lament soaring prices of, well, everything, after shelter and rent costs, the second biggest drain of US household income and savings is insurance premiums.

https://www.zerohedge.com/health/shock-35-trillion-healthcare-industry-trump-admin-will-force-hospitals-disclose-secret

November 7, 2019

Tariff Update

China says it has agreed with U.S. to cancel tariffs in phases

* Tariffs imposed during months-long war to be cancelled in phases

* Commerce ministry spokesman does not specify timetable

* Both sides must simultaneously scrap some tariffs

* Comments follow “serious and constructive” discussions (adds China considering lifting restrictions on U.S. poultry imports, market reactions)

By Yawen Chen and Martin Pollard

BEIJING, Nov 7 (Reuters) – China and the United States have agreed to cancel in phases the tariffs imposed during their months-long trade war, the Chinese commerce ministry said on Thursday, without specifying a timetable.

An interim U.S.-China trade deal is widely expected to include a U.S. pledge to scrap tariffs scheduled for Dec. 15 on about $156 billion worth of Chinese imports, including cell phones, laptop computers and toys.

Tariff cancellation was an important condition for any agreement, ministry spokesman Gao Feng said, adding that both must simultaneously cancel some tariffs on each other’s goods to reach a “phase one” trade deal.

“The trade war started with tariffs, and should end with the cancellation of tariffs,” Gao told a regular news briefing.

The proportion of tariffs cancelled for both sides to reach a “phase one” deal must be the same, but the number to be cancelled can be negotiated, he added, without elaborating.

“In the past two weeks, the lead negotiators from both sides have had serious and constructive discussions on resolving various core concerns appropriately,” Gao said.

“Both sides have agreed to cancel additional tariffs in different phases, as both sides make progress in their negotiations.”

He did not give a timeline.

In what could be another gesture to boost optimism, China’s state news agency Xinhua reported late on Thursday that the Chinese customs and the Ministry of Agriculture are considering removing restrictions on U.S. poultry imports.

China has banned all U.S. poultry and eggs since January 2015 due to an avian influenza outbreak.

Beijing’s signal that a ‘phase 1’ trade deal with the United States was close to being sealed helped Europe’s share markets hit a more than 4-year peak on Thursday and bond yields shuffled higher.

TRUMP-XI MEETING

A source previously told Reuters that Chinese negotiators wanted the United States to drop 15% tariffs on about $125 billion worth of Chinese goods that took effect on Sept. 1.

They also sought relief from earlier 25% tariffs on about $250 billion of imports, ranging from machinery and semiconductors to furniture.

A person familiar with China’s negotiating position said it was pressing Washington to “remove all tariffs as soon as possible”.

A deal may be signed this month by U.S. President Donald Trump and Chinese President Xi Jinping at a yet-to-be determined location.

Dozens of venues have been suggested for a meeting, which had originally been set to take place on the sidelines of a now-cancelled mid-November summit of Asia-Pacific leaders in Chile, a senior Trump administration official told Reuters on Wednesday.

One possible location was London, where the leaders could meet after a NATO summit that Trump is due to attend from Dec. 3-4, the official said.

Gao declined to say when and where such a meeting could be.

Since Trump took office in 2017, his administration has been pressing China to curb massive subsidies to state-owned firms and end the forced transfer of American technology to Chinese firms as a price of doing business in China. (Reporting by Yawen Chen and Martin Pollard; Writing by Ryan Woo; Editing by Kim Coghill, Clarence Fernandez & Simon Cameron-Moore)

https://www.agriculture.com/markets/newswire/update-3-china-says-it-has-agreed-with-us-to-cancel-tariffs-in-phases

November 7, 2019

Tariff Update

China says it has agreed with U.S. to cancel tariffs in phases

* Tariffs imposed during months-long war to be cancelled in phases

* Commerce ministry spokesman does not specify timetable

* Both sides must simultaneously scrap some tariffs

* Comments follow “serious and constructive” discussions (adds China considering lifting restrictions on U.S. poultry imports, market reactions)

By Yawen Chen and Martin Pollard

BEIJING, Nov 7 (Reuters) – China and the United States have agreed to cancel in phases the tariffs imposed during their months-long trade war, the Chinese commerce ministry said on Thursday, without specifying a timetable.

An interim U.S.-China trade deal is widely expected to include a U.S. pledge to scrap tariffs scheduled for Dec. 15 on about $156 billion worth of Chinese imports, including cell phones, laptop computers and toys.

Tariff cancellation was an important condition for any agreement, ministry spokesman Gao Feng said, adding that both must simultaneously cancel some tariffs on each other’s goods to reach a “phase one” trade deal.

“The trade war started with tariffs, and should end with the cancellation of tariffs,” Gao told a regular news briefing.

The proportion of tariffs cancelled for both sides to reach a “phase one” deal must be the same, but the number to be cancelled can be negotiated, he added, without elaborating.

“In the past two weeks, the lead negotiators from both sides have had serious and constructive discussions on resolving various core concerns appropriately,” Gao said.

“Both sides have agreed to cancel additional tariffs in different phases, as both sides make progress in their negotiations.”

He did not give a timeline.

In what could be another gesture to boost optimism, China’s state news agency Xinhua reported late on Thursday that the Chinese customs and the Ministry of Agriculture are considering removing restrictions on U.S. poultry imports.

China has banned all U.S. poultry and eggs since January 2015 due to an avian influenza outbreak.

Beijing’s signal that a ‘phase 1’ trade deal with the United States was close to being sealed helped Europe’s share markets hit a more than 4-year peak on Thursday and bond yields shuffled higher.

TRUMP-XI MEETING

A source previously told Reuters that Chinese negotiators wanted the United States to drop 15% tariffs on about $125 billion worth of Chinese goods that took effect on Sept. 1.

They also sought relief from earlier 25% tariffs on about $250 billion of imports, ranging from machinery and semiconductors to furniture.

A person familiar with China’s negotiating position said it was pressing Washington to “remove all tariffs as soon as possible”.

A deal may be signed this month by U.S. President Donald Trump and Chinese President Xi Jinping at a yet-to-be determined location.

Dozens of venues have been suggested for a meeting, which had originally been set to take place on the sidelines of a now-cancelled mid-November summit of Asia-Pacific leaders in Chile, a senior Trump administration official told Reuters on Wednesday.

One possible location was London, where the leaders could meet after a NATO summit that Trump is due to attend from Dec. 3-4, the official said.

Gao declined to say when and where such a meeting could be.

Since Trump took office in 2017, his administration has been pressing China to curb massive subsidies to state-owned firms and end the forced transfer of American technology to Chinese firms as a price of doing business in China. (Reporting by Yawen Chen and Martin Pollard; Writing by Ryan Woo; Editing by Kim Coghill, Clarence Fernandez & Simon Cameron-Moore)

https://www.agriculture.com/markets/newswire/update-3-china-says-it-has-agreed-with-us-to-cancel-tariffs-in-phases

October 21, 2019

ECHA Regulations Affect Epoxies

ECHA has published its ninth recommendation to the European Commission prioritising 18 SVHCs to be added to the REACH Authorisation list (Annex XIV).  The public consultation, on the draft recommendation ended in December 2018, followed by the adoption of the Member State Committee Opinion on 26 June 2019.  This endorsed the addition of all 18 substances to the Authorisation list.

The hazard profiles of the 18 substances include 13 that are toxic for reproduction, of which one is also an endocrine disruptor, and two respiratory sensitisers. The remaining substances include an endocrine disruptor, a carcinogen and a vPvB substance.

Uses include:

  •  Epoxy resin hardeners
    • Bisphenol A
    • HHPA
    • MHHPA
  • Polymer stabilisers
    • Reaction mass of DOTE and MOTE
    • DOTE (2-ethylhexyl 10-ethyl-4,4-dioctyl-7-oxo-8-oxa-3,5-dithia-4-stannatetradecanoate)
  • PVC stabilisers
    • Trilead dioxide phosphonate
    • Dioxobis(stearato)trilead
    • Fatty acids, C16-18, lead salts
  • Flame retardant
    • Dechlorane PlusTM
  • Aviation fuel
    • Tetraethyllead
  • Printing ink
    • Trityl alcohol
  • Solvents
    • 2-methoxyethanol
    • 2-ethoxyethanol
  • Artist paints
    • Trilead bis(carbonate) dihydroxide
  • Mirror backing
    • Lead oxide sulfate
    • Trilead dioxide phosphonate
  • Lubricants/greases
    • RP-HP

A number of substances listed in the ninth recommendation are currently not manufactured or imported into the EU, but have been included in the recommendation to avoid future cases of regrettable substitution.

A range of Latest Application Dates have been assigned from 18 to 24 months.

The European Council will start the process of progressing the prioritised substances via its comitology procedure to decide which will be included in Annex XIV.  Any final decisions will be dependent on the support of the European Council and European Parliament, who exercise a formal right of scrutiny.

This recommendation serves as a is a timely reminder that horizon scanning and supply chain mapping activities remain a critical consideration to minimise future business risks and ensure continuity of supply.

RPA is very well versed in providing such services to a variety of international clients.  If you would like to find out more about RPA’s REACH compliance services, please click here or contact us with any questions.

ECHA Proposes 18 Substances for Authorisation